From GlobeNewswire: 2025-05-12 16:05:00

Crinetics Pharmaceuticals, Inc. granted non-qualified stock option awards to purchase 152,475 shares and 101,800 restricted stock units to 35 new non-executive employees under the 2021 Inducement Plan on May 10, 2025. The stock options have an exercise price of $30.68 per share, vesting over four years, while the RSUs will also vest over four years in equal annual installments. Crinetics focuses on developing therapeutics for endocrine diseases and tumors, with lead candidate paltusotine in clinical development for acromegaly and carcinoid syndrome, and atumelnant in development for congenital adrenal hyperplasia and Cushing’s disease.



Read more at GlobeNewswire: Crinetics Pharmaceuticals Announces May 2025 Inducement